Free tool
Drug Trial Radar: Respiratory
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
18
Not yet recruiting, industry sponsors, Respiratory, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed931
18 trials
Showing 1 to 18, recently updated first.
- A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)Pivotal-lookingNot yet recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07915219 · 1,500 participants (planned) · Start Jan 11, 2027 · Primary completion Jul 31, 2029
Drug: verducatib · For: Bronchiectasis
Sites: Birmingham, Alabama; Tucson, Arizona; Newport Beach, California · 394 sites in all
- The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary DiseasePivotal-lookingNot yet recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07907991 · 1,800 participants (planned) · Start Mar 10, 2027 · Primary completion Nov 12, 2029
Drug: Verducatib; Placebo matching verducatib · For: Chronic Obstructive Pulmonary Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; La Palma, California · 26 sites in all
- Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary FibrosisPivotal-lookingNot yet recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07441408 · 2,380 participants (planned) · Start Dec 16, 2026 · Primary completion Nov 22, 2029
Drug: BMS-986278 · For: Pulmonary Fibrosis
Sites: Birmingham, Alabama; Ocala, Florida; Philadelphia, Pennsylvania · 275 sites in all
- Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)Pivotal-lookingNot yet recruiting
Eurofarma Laboratorios S.A.Industry
NCT06234345 · 1,252 participants (planned) · Start Jan 30, 2027 · Primary completion Aug 2028
Drug: Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg; Comparator - Trimbow® · For: Chronic Obstructive Pulmonary Disease
Sites: São Paulo, Brazil
- Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With AsthmaPivotal-lookingNot yet recruiting
Chiesi Farmaceutici S.p.A.Industry
NCT07858123 · 700 participants (planned) · Start Nov 16, 2026 · Primary completion Jun 26, 2030
Drug: CHF5993 100/6/12.5 μg pMDI HFA-152a; Seretide Evohaler · For: Asthma
Sites: Frankfurt, Germany; Göttingen, Germany; Jena, Germany · 25 sites in all
- A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingNot yet recruiting
Regend TherapeuticsIndustry
NCT07828353 · 102 participants (planned) · Start Oct 2026 · Primary completion Sep 2028
Drug: Placebo; REGEND001 · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Guangzhou, China
- A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary FibrosisPivotal-lookingNot yet recruiting
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT07719023 · 263 participants (planned) · Start Aug 31, 2026 · Primary completion Sep 30, 2028
Drug: AK3280; Placebo and 1 more · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Beijing, China
- A Study to Evaluate the Efficacy and Safety of CHF10196 Tablets (Florensocatib) Compared With Placebo in Male and Female Participants 12 to 85 Years of Age With BronchiectasisPivotal-lookingNot yet recruiting
Chiesi Farmaceutici S.p.A.Industry
NCT07577804 · 904 participants (planned) · Start Nov 2026 · Primary completion Apr 2030
Drug: CHF10196 tablets (florensocatib); Placebo · For: Bronchiectasis
- A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPDPivotal-lookingNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07658339 · 387 participants (planned) · Start Jul 11, 2026 · Primary completion Jun 11, 2027
Drug: HSK39004 Inhalation Suspension; Placebo control · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Beijing, China
- Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)Pivotal-lookingNot yet recruiting
Inhibikase TherapeuticsIndustry
NCT07632898 · 484 participants (planned) · Start Oct 23, 2026 · Primary completion Jun 30, 2030
Drug: IKT-001 · For: Pulmonary Arterial Hypertension (PAH)
- Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPDPivotal-lookingNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07634367 · 300 participants (planned) · Start Jul 10, 2026 · Primary completion Dec 24, 2027
Drug: HSK39004 Inhalation Suspension · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Nanchang, China
- A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional LimitationsPivotal-lookingNot yet recruiting
VIVUS LLCIndustry
NCT07612657 · 300 participants (planned) · Start May 29, 2026 · Primary completion May 31, 2028
Drug: VI-0106; Placebo · For: Pulmonary Arterial Hypertension; Pulmonary Arterial Hypertension (PAH); Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) and 2 more
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary FibrosisPivotal-lookingNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07519070 · 420 participants (planned) · Start Apr 5, 2026 · Primary completion Apr 5, 2028
Drug: HSK44459; HSK44459 and 4 more · For: IPF
- A Phase 3 Trial of JKN2401 Injection in COPDPivotal-lookingNot yet recruiting
Joincare Pharmaceutical Group Industry Co., LtdIndustry
NCT07330310 · 888 participants (planned) · Start Mar 2026 · Primary completion Sep 2027
Drug: JKN2401 Injection · For: Chronic Obstructive Pulmonary Disease (COPD)
- Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe AsthmaPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07302516 · 636 participants (planned) · Start Dec 25, 2025 · Primary completion Dec 2028
Drug: tezepelumab (Arm1&Arm2) · For: Asthma
- Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingNot yet recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07147946 · 666 participants (planned) · Start Sep 2025 · Primary completion Mar 2027
Drug: TQC3721 Suspension for inhalation; Placebo of TQC3721 Suspension for Inhalation · For: Chronic Obstructive Pulmonary Disease
Sites: Bozhou, China; Chizhou, China; Hefei, China · 76 sites in all
- A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingNot yet recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT06547333 · 884 participants (planned) · Start Sep 13, 2024 · Primary completion Apr 29, 2032
Drug: CM310; Placebo · For: Chronic Obstructive Pulmonary Disease
- Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen ExtractPivotal-lookingNot yet recruiting
Inmunotek S.L.Industry
NCT05641272 · 90 participants (planned) · Start Nov 1, 2023 · Primary completion Jun 1, 2026
Drug: 3,000 MM09; 9,000 MM09 · For: Allergic Rhinitis; Allergic Asthma; Allergic Rhinoconjunctivitis and 1 more
Sites: Buenos Aires, Argentina
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.